Connor, Clark & Lunn Investment Management (CC&L)
MEDP icon

Connor, Clark & Lunn Investment Management (CC&L)’s Medpace MEDP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.4M Sell
110,353
-24,485
-18% -$11.3M 0.11% 169
2026
Q1 		$64.7M Sell
134,838
-7,518
-5% -$3.85M 0.15% 147
2025
Q4 		$80M Buy
142,356
+13,757
+11% +$7.81M 0.21% 104
2025
Q3 		$66.1M Sell
128,599
-30,253
-19% -$13.2M 0.21% 87
2025
Q2 		$49.9M Buy
158,852
+72,286
+84% +$21.7M 0.18% 107
2025
Q1 		$26.4M Buy
86,566
+21,150
+32% +$7.11M 0.12% 149
2024
Q4 		$21.7M Buy
65,416
+38,991
+148% +$13.2M 0.1% 159
2024
Q3 		$8.82M Buy
26,425
+21,764
+467% +$8.27M 0.04% 312
2024
Q2 		$1.92M Sell
4,661
-1,844
-28% -$730K 0.01% 666
2024
Q1 		$2.63M Sell
6,505
-1,522
-19% -$535K 0.01% 602
2023
Q4 		$2.46M Sell
8,027
-11,893
-60% -$3.21M 0.01% 617
2023
Q3 		$4.82M Buy
19,920
+5,956
+43% +$1.52M 0.03% 408
2023
Q2 		$3.35M Buy
13,964
+10,940
+362% +$2.27M 0.02% 474
2023
Q1 		$569K Sell
3,024
-22,430
-88% -$4.64M ﹤0.01% 847
2022
Q4 		$5.41M Sell
25,454
-8,430
-25% -$1.68M 0.03% 342
2022
Q3 		$5.33M Buy
33,884
+2,115
+7% +$337K 0.03% 315
2022
Q2 		$4.75M Buy
31,769
+9,688
+44% +$1.4M 0.03% 321
2022
Q1 		$3.61M Sell
22,081
-3,110
-12% -$513K 0.02% 384
2021
Q4 		$5.48M Buy
25,191
+3,696
+17% +$774K 0.03% 322
2021
Q3 		$4.07M Buy
21,495
+12,185
+131% +$2.22M 0.02% 380
2021
Q2 		$1.64M Buy
+9,310
New +$1.61M 0.01% 581
2019
Q3 		– Sell
-85,425
Closed -$5.59M – 1038
2019
Q2 		$5.59M Sell
85,425
-12,031
-12% -$693K 0.04% 262
2019
Q1 		$5.75M Sell
97,456
-65,977
-40% -$3.94M 0.04% 259
2018
Q4 		$8.65M Buy
163,433
+41,762
+34% +$2.29M 0.06% 203
2018
Q3 		$7.29M Buy
121,671
+105,271
+642% +$5.76M 0.04% 255
2018
Q2 		$705K Buy
16,400
+7,925
+94% +$320K ﹤0.01% 695
2018
Q1 		$296K Buy
+8,475
New +$310K ﹤0.01% 620

Other funds holding MEDP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s MEDP Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Medpace (MEDP) stake by 18% in Q2 2026, selling an estimated $11.3M and leaving 110,353 shares worth $58.4M. The position accounts for 0.11% of the portfolio, ranked #169.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in MEDP in Q1 2018 and has held it in 27 quarters since. The position peaked at $80M in Q4 2025. 693 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 110,353 shares of Medpace worth $58.4M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 24,485 Medpace shares in Q2 2026, an estimated $11.3M.
  • Medpace made up 0.11% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #169 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Medpace in Q1 2018 and has held it in 27 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Medpace position peaked at $80M in Q4 2025.
  • 693 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.